Novo Nordisk A/S (NYSE:NVO) Stock Position Trimmed by Broderick Brian C

Broderick Brian C reduced its holdings in Novo Nordisk A/S (NYSE:NVO) by 5.4% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 6,091 shares of the company’s stock after selling 349 shares during the quarter. Broderick Brian C’s holdings in Novo Nordisk A/S were worth $725,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently modified their holdings of the business. GQG Partners LLC raised its holdings in Novo Nordisk A/S by 654.6% during the first quarter. GQG Partners LLC now owns 3,633,064 shares of the company’s stock worth $466,485,000 after purchasing an additional 3,151,584 shares in the last quarter. International Assets Investment Management LLC boosted its position in shares of Novo Nordisk A/S by 10,608.4% in the third quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company’s stock worth $215,942,000 after buying an additional 1,796,635 shares during the period. DSM Capital Partners LLC grew its stake in Novo Nordisk A/S by 257,816.0% during the 2nd quarter. DSM Capital Partners LLC now owns 1,593,921 shares of the company’s stock valued at $227,516,000 after acquiring an additional 1,593,303 shares in the last quarter. Acadian Asset Management LLC grew its holdings in shares of Novo Nordisk A/S by 1,300.8% during the 1st quarter. Acadian Asset Management LLC now owns 1,244,128 shares of the company’s stock valued at $159,703,000 after acquiring an additional 1,155,313 shares in the last quarter. Finally, Mediolanum International Funds Ltd purchased a new stake in shares of Novo Nordisk A/S during the 3rd quarter worth about $98,765,000. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Down 1.5 %

Shares of NVO opened at $105.35 on Friday. The business’s fifty day moving average price is $119.68 and its two-hundred day moving average price is $129.92. The firm has a market capitalization of $472.76 billion, a price-to-earnings ratio of 34.09, a PEG ratio of 1.31 and a beta of 0.42. Novo Nordisk A/S has a 52 week low of $94.73 and a 52 week high of $148.15. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94.

Analyst Upgrades and Downgrades

Several research firms have weighed in on NVO. Cantor Fitzgerald restated an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. StockNews.com raised Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research report on Friday, November 1st. Finally, BMO Capital Markets lowered their target price on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating on the stock in a research note on Thursday, October 17th. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $144.50.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.